Stopping treatment may allow gradual return to pre-treatment patterns
One part of the BA is reabsorbed in the ileum and returned to the liver through the portal vein
Related Articles and Topics: Nrf2 Pathway: Increasing the Bodys Ability to Get Rid of Toxins References: Amors, Rubn, et al
Live bacterial strains: Lacticaseibacillus paracasei PXN37, Lactiplantibacillus plantarum PXN47, Lacticaseibacillus rhamnosus PXN54, Bacillus subtilis PXN21, Bifidobacterium bifidum PXN23, Bifidobacterium breve PXN25, Bifidobacterium longum PXN30, Lactobacillus helveticus PXN35, Lactococcus lactis ssp
Standard Weekly Dose Escalation Protocol Dose Escalation Criteria Advance to the next dose level after 4 weeks if: Tolerated current dose with minimal side effects Adequate clinical response observed Patient adherence maintained No contraindications developed Dose Adjustment for Side Effects If significant gastrointestinal side effects occur: Maintain current dose for an additional 24 weeks Consider temporary dose reduction Provide symptomatic management Re-escalate when tolerated Individualization Tailor titration based on: Patient tolerance and side effects Therapeutic response Clinical goals Comorbid conditions Clinical Pearls: Gradual titration significantly reduces the incidence and severity of gastrointestinal side effects (nausea, vomiting, diarrhea) that are common during initiation of GLP-1 receptor agonist therapy
